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Introduction
Major hepatectomy carries a significant risk of mortality. In
patients with normal liver bearing metastases, mortality
after major hepatectomy ranges from 0.5% to 4%, but in
patients [1] with chronic liver disease, such as cholestatic
or cirrhotic liver, mortality increases to 4% to 12% [2, 3].
The main cause of mortality as well as postoperative
morbidity after major hepatic resection is liver insuffi-
ciency, often due to an insufficient liver remnant volume
[4, 5]. It has been demonstrated from animal experiments
and clinical data that redirection of the portal flow toward a
part of the liver will induce hypertrophy of this part. This
redirection of portal flow can be obtained by surgical
ligation or by percutaneous embolization (PVE). Today,
PVE is preferred to surgical ligation to avoid additional
surgery. However, when surgery is performed, usually for
resection of the primary tumor, and portal vein flow
redistribution is required, no clear recommendations can be
given regarding whether it is preferable to carry out per-
cutaneous PVE in a second step or ligation at the time of
surgery. Some studies have reported greater hypertrophy
after PVE [6], whereas others have reported no differences
in hypertrophy [7]. The aim of PVE is to (1) preoperatively
increase the volume of the future liver remnant to enable
surgery and (2) to decrease postoperative morbidity when
the only contraindication to surgery is an initially insuffi-
cient remnant liver.
Definitions
Future liver remnant (FLR) is the liver that will be left in
place after surgery and that was not targeted by emboliza-
tion. The FLR must hypertrophy after portal vein emboli-
zation (PVE). Most teams wait 4 weeks before surgery.
FLR hypertrophy must be measured by way of computed
axial tomography (CAT) examination after injection of
iodine with volumetric measurements of the FLR segments,
with the results compared with the measurements per-
formed before PVE using the same technique.
Hypertrophy can be quantified as FLR hypertrophy,
which is defined as the difference between FLR after a
waiting period from 3 to 6 weeks after PVE minus FLR
before PVE divided by FLR before PVE. The waiting period
must be long enough to allow hypertrophy and as short as
possible to avoid tumor growth, which precludes surgery.
Hypertrophy can also be quantified by increased FLR ratio.
The FLR ratio is defined as (FLR volume—tumor in the
FLR)/(total liver volume—total tumor volume) [8].
Technical success of PVE is defined by a complete
occlusion of portal branches feeding the future resected
liver segments. Branches of the FLR must be patent with
hepatopetal flow. In the late phase of control portography,
parenchymography must be visible only in the FLR.
Clinical success is considered to occur when the patient
reaches the volumetric criteria for liver resection.
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Major hepatic resection (or major hepatectomy) is
defined as a resection of at least four of eight segments of
the liver. Right hepatectomy is defined as a resection of
segments V to VIII. Extended right hepatectomy addi-
tionally includes segment IV.
Resection rate is defined as the number of embolized
patients that will ultimately be resected.
Materials and Methods
Patient Selection
Patients must be candidates for major hepatectomy or major
hepatectomy associated with radiofrequency ablation on the
FLR. This decision should be made in the context of a tumor
board meeting that includes surgeons, hepatologists, on-
cologists, and interventional radiologists. The only contra-
indication to liver resection must be the initially insufficient
volume of the FLR. PVE indication is determined by the
liver volumetry obtained from liver CAT [9].
Liver volumetry is calculated manually from CAT slices
after injection of contrast media, preferably in the portal or
equilibrium phase to opacify all of the portal and hepatic
veins. Slice thickness B5 mm is recommended. The FLR is
determined according to the future resection plane in col-
laboration with the surgical team. If radiofrequency abla-
tion (RFA) is planned on a tumor in the FLR, the expected
volume of RFA must be taken into consideration and
subtracted from the FLR volume. Tumor tissue must not be
taken into consideration for volumetric evaluation because
volumetry must evaluate liver tissue only.
Blood tests—including liver enzyme, bilirubin level,
partial thromboplastin time, prothrombin time (PT), and
platelet count must be obtained before PVE. Criteria to
propose PVE are different according to the liver status and
to the tumor involvement as follows:
Patients with Tumors that Developed in Normal
Underlying Liver Parenchyma
PVE is recommended when the FRL-to-total liver ratio is
\25 to 30 [7, 10, 11]. The indication of PVE can be
extended to a 40% FLR ratio in patients having received
chemotherapy or showing abnormal indocyanine green test
results (or other abnormal liver function tests) [10, 12, 13].
Patients with Tumors that Develop in Chronic Liver
Disease and Cirrhosis States
In such cases, the decision is based either on liver volume
or on liver volume plus estimation of overall liver function
by indocyanin green retention rate at 15 min (ICCG 15).
An FRLR of 40% is recommended when the ICCG 15 is
between 10% and 20%. When the ICCG 15 is [20%, an
FRLR of 50% is recommended [12–14].
Patients with Tumors Invading the Biliary Tree Associated
with Cholestasis
Because biliary obstruction has impaired liver regeneration
and hypertrophy, the biliary tree of the FRL must be
drained first, and PVE can be performed secondarily. The
indication is an FRLR \40% [15].
Contraindication for PVE [11]
PVE is contraindicated in the following types of patients:
1. Tumors invading the portal vein
(a) Portal hypertension (blocked to free hepatic vein
pressure gradient [12 mmHg)
2. Coagulation disorders (PT \ 60%, platelet count \50
G/l)
(a) Even if previous transarterial chemoembolization
(TACE) may improve PVE results [16], a min-
imum of 3-week delay between TACE and PVE
is recommended.
Patient Information to be Given Before Treatment
Patients should be informed that this procedure is not an
antitumoral treatment but a treatment made to increase
safety or to enable a surgical procedure. Minor complica-
tions are encountered in 20% to 25% of cases and are
mainly associated with slight fever and abdominal dis-
comfort and pain. Major complications are infrequent and
mainly include infection and subcapsular hematoma,
hemobilia, and portal vein thrombosis (\2% of cases).
Mortality due to PVE has not been reported.
When tumors (usually small nodules) are present in the
nonembolized lobe, it must be explained to the patient that
those lesions might increase in size more quickly due to
PVE [17]. Patients must also be told that the efficacy of the
procedure can be estimated approximately 4 weeks after
PVE by way of CAT with injection of contrast media and
liver volumetry.
Embolization Method
Access to the portal system should be done under ultra-
sound guidance to puncture a peripheral branch [8]. Access
can be obtained by way of controlateral approach (i.e.,
puncture of the left portal branch and embolization of the
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right portal branches) or ispsilateral approach (puncture of
the right portal branch to embolize right portal branches.
The advantage of the controlateral approach is easier
catheterization, but there is a risk of damage to the FLR.
Five-French materials (catheter or introductory sheath)
are usually recommended. The catheter should be placed at
the splenomesenteric confluence to perform a portography
to visualize portal anatomy, including its variations, and to
localize segment IV branches. Measurement of portal
pressure is not routinely performed in patients with normal
liver. In cirrhotic patients, measuring the portal and central
venous pressures is useful to determine whether the patient
has a portostemic gradient [12 mmHg in, which case the
patient is at major risk of perisurgical complications [18,
19]. These patients are not eligible for PVE.
The aim of embolization is complete obstruction of the
targeted branches and redistribution of flow to the FLR
branches only. Final portography is mandatory to verify
this objective. A final pressure measurement should be
obtained at the end of the procedure in patients with
chronic liver disease to document portal pressure increase,
which is usually approximately 3 mmHg. Embolization of
segment IV branches is recommended in patients with
tumors who are undergoing extended right hepatectomy.
However, if embolization of that segment causes risk of
reflux into the portal branch of the FRL, such embolization
must not be performed because any major reflux into FRL
portal branches might preclude surgery.
Various embolic materials have been used. Some
products are not recommended due to reported recanali-
zation or lower induced hypertrophy as follows:
Gelfoam
Gelfoam is associated with a high rate of portal vein recan-
alization and seems less efficient than other products [8].
Nonspherical Polyvinyl Alcohol Particles
Polyvinyl alcohol particles (PVA) have been used but are
less efficient than spherical particles [20].
Alcohol
Direct intraportal injection has been described. Although
efficient, it is hard to control and has been associated with
significant morbidity (liver necrosis, portal vein thrombo-
sis) [21].
Drug-Loadable Embols
These have not been reported in PVE and cannot be
recommended.
Recommended products [14, 20, 22] include the
following:
Mixture of n-Butyl-cyanoacrylate and Iodized Oil
This has been described extensively as showing good
results and low morbidity. Usually a mixture of one part n-
butyl-cyanoacrylate (NBCA) to one or to parts lipiodol is
used. Injections of small aliquots in between abundant
flushing with nonionic liquid, such as dextran or glucose
5%, is the most commonly reported technique.
Spherical Microparticles
These are associated with coil embolization, which is
mostly described in North American reports, and have been
reported to be superior to nonspherical PVA. It seems as
efficient as NBCA, although it has never been compared in
randomized trials. Most teams start with 300- to 500-lm
particles and finish with 700- to 900-lm particles. Coils are
used at the end of the procedure to allow for complete
occlusion of the proximal trunk. It is advisable to avoid all
too proximal occlusions and rather leave 1 cm unembol-
ized segment of the right portal branch to facilitate surgical
ligation at the time of liver resection.
Association of Fibrin Glue with Iodized Oil
This has mostly been described in Japan and has the
drawback of requiring special catheters that are only
available in Asia.
Medication and Periprocedural Cure
PVE can be carried out as an outpatient procedure when
conscious sedation is used. A 1- or 2-day hospital stay is
recommended, as reported by most teams using either
conscious sedation associated with local anesthesia or
general anesthesia.
There is no consensus on the use of antibiotics, and the
type of antibiotics and the length of treatment vary from
one report to another [11], except in patients with an
associated biliary procedure. Because little to no liver tis-
sue necrosis is found after PVE if an antibiotic is given, it
must be administered for a very short period of time, from
a single dose to 48 h. Mild to moderate abdominal pain
after PVE has been reported in 20% to 30% of patients and
is usually easily controlled by oral analgesia. Use of pure
alcohol as embolic material is associated with more severe
abdominal pain.
Biologic tests are not mandatory after the procedure.
Slightly increased aspartate aminotransferase and alanine
aminotransferase levels with a peak at day 3 after the
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procedure have been reported, but these are without clini-
cal significance.
Results [14]
The technical success rate should be close to 100%. Few
cases of failures or repeated procedures have been reported
in the literature. The resection rate should be approxi-
mately 85%. This rate may decrease to 70% in the case of
cirrhotic patients. Reasons for nonresection are tumor
progression, peritoneal metastases, or unsuspected metas-
tases discovered at laparotomy. Absence of hypertrophy is
rare, \10% in metastatic liver, but it can reach 20% in
cirrhotic patients.
In patients with normal liver and liver metastases, the
increase of the FLR ratio is between 8% and 25%, and
regeneration is always observed after PVE. In cirrhotic
patients, PVE fails to induce left-lobe hypertrophy in 20%
of cases. Increased rate of FLR ratio in this population is
slightly lower, between 6% and 20%.
Recent studies have demonstrated that hypertrophy is
inversely proportional to the FRL ratio before PVE,
meaning that the smaller FRL before PVE will have the
larger hypertrophy. Consequently there is no lower limit
for the FRL ratio to perform PVE.
Complications [14, 23]
In terms of complications (Table 1), a rate of minor com-
plications (20% to 25%) is considered acceptable. With
major complications, this rate should be \5% and should
not preclude further liver resection. Except for inadvertent
embolization, most complications will occur in the punc-
tured lobe, which is an argument in favour of a homolateral
approach. However, complication rates for homolateral and
controlateral approaches are the same. Reported in the
literature as the only factor increasing complications is
puncture of the posterior segment versus puncture of the
anterior segment [24], thus advocating puncture of the
anterior segment when compatible with the location of the
PVE to be performed.
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in FRL without portal thrombosis
0.2 0.4
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